DISUTILITIES ASSOCIATED WITH INTRAVENOUS IRON INFUSIONS: RESULTS FROM A TIME TRADE-OFF SURVEY AND DIMINISHING MARGINAL UTILITY MODEL IN CHINA

ELECTRONIC SUPPLEMENTARY MATERIAL

Shanlian Hu¹; Depei Wu²; Jing Wu³; Yabing Zhang⁴; Mette Bøgelund⁵; Johannes Pöhlmann⁶; Richard F. Pollock^{6*}

¹ School of Public Health, Fudan University, Shanghai, China

² First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China

³ School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China

⁴ Shanghai Institute of Technology, Shanghai, China

⁵ Incentive Partners ApS, Holte, Denmark

⁶Covalence Research Ltd., Harpenden, United Kingdom

*Corresponding author Richard F. Pollock Covalence Research Ltd, Rivers Lodge, West Common, Harpenden, AL5 2JD, United Kingdom pollock@covalence-research.com +44 (0) 20 8638 6525

Table S1 Description of illness presented to survey participants (English version)

Item	Implementation in the survey		
	Now we would like you to imagine having a non-fatal chronic disease.		
Textual description	The illness impacts how you feel. This means that you feel fatigued all day long, and that your breathing is very heavy, and you can feel your heart beating strongly, particularly when you walk the stairs or carry a heavy bag. You can feel dizzy when standing up from a chair. The fatigue is not only physical but also mental; this means you will feel as if your brain is clouded and you have headaches and difficulties performing mental and physical tasks.		
	The illness can be treated, and the treatment will significantly reduce your fatigue and normalize your breathing and physical and mental function.		
	The treatment is given as infusions in a larger hospital (not community hospital). An infusion is a way of providing you the medication through a drip into a vein in your arm. You will be treated as an outpatient patient and will be able to have the infusion while sitting in a chair, so you won't have to undress. A health care professional will cleanse your skin with an alcohol wipe before inserting the needle with the medication.		
	[visual aid, see below]		
	The insertion of the needle into your vein can hurt a bit (corresponding to the feeling of having a blood sample taken). During the infusion you may experience redness and small rashes in area of the skin where the infusion is given. Redness and rashes are not dangerous but might be a bit uncomfortable and itch a bit.		
	You might also experience nausea and that your heart rate increases. You will have a small wound where the needle entered your vein and will be offered a bandage. For up to a day following the treatment you may experience flu like symptoms.		
	You will need to travel to the hospital every time you need the treatment. Also, you will spend time getting prepared and waiting for your appointment. After the infusion you will need to stay in the hospital for 30 minutes to make sure you do not get any adverse reactions to the treatment.		
Visual aid	OPharmacosmos A/S.		

Table S2Description of health states and time trade-offs presented to survey participants (English version)

Health state ID	Description	Time trade-off	
1	We would now like you to imagine that you have the non-fatal chronic disease described previously.	The yearly treatment course includes getting 1 infusion lasting 30–60 minutes at the hospital.	
	You get treatment for it every year.	There will be no risk of serious long-term side effects (softening of/fractured bones).	
	Each treatment consists of getting 1 infusion lasting 30-60 minutes at the hospital.		
	There will be no risk of serious long-term side effects (softening of/fractured bones).		
	This treatment keeps the disease under control.		
	Imagine what it would be like for you to live with this disease and get the described treatment for the rest of your life.		
2	We would now like you to imagine that you have the non-fatal chronic disease described previously.	The yearly treatment course includes getting 2 infusions lasting 30–60 minutes at the hospital.	
	You get treatment for it every year.	There will be no risk of serious long-term side effects (softening of/fractured bones).	
	Each treatment consists of getting 2 infusions lasting 30-60 minutes at the hospital.		
	There will be no risk of serious long-term side effects (softening of/fractured bones).		
	This treatment keeps the disease under control.		
	Imagine what it would be like for you to live with this disease and get the described treatment for the rest of your life.		
3	We would now like you to imagine that you have the non-fatal chronic disease described previously.	The yearly treatment course includes getting 5 infusions lasting 30–60 minutes at the hospital.	
	You get treatment for it every year.	There will be no risk of serious long-term side effects (softening of/fractured bones).	
	Each treatment consists of getting 5 infusions lasting 30-60 minutes at the hospital.		
	There will be no risk of serious long-term side effects (softening of/fractured bones).		
	This treatment keeps the disease under control.		
	Imagine what it would be like for you to live with this disease and get the described treatment for the rest of your life.		
4	We would now like you to imagine that you have the non-fatal chronic disease described previously.	The yearly treatment course includes getting 7 infusions lasting 30–60 minutes at the hospital.	
	You get treatment for it every year.	There will be no risk of serious long-term side effects (softening of/fractured bones).	
	Each treatment consists of getting 7 infusions lasting 30-60 minutes at the hospital.		
	There will be no risk of serious long-term side effects (softening of/fractured bones).		

Health state ID	Description	Time trade-off	
	This treatment keeps the disease under control.		
	Imagine what it would be like for you to live with this disease and get the described treatment for the rest of your life.		
5	We would now like you to imagine that you have the non-fatal chronic disease described previously.	The yearly treatment course includes getting 1 infusion lasting 15–30 minutes at the hospital.	
	You get treatment for it every year.	There will be no risk of serious long-term side effects (softening of/fractured bones).	
	Each treatment consists of getting 1 infusion lasting 15-30 minutes at the hospital.		
	There will be no risk of serious long-term side effects (softening of/fractured bones).		
	This treatment keeps the disease under control.		
	Imagine what it would be like for you to live with this disease and get the described treatment for the rest of your life.		
6	We would now like you to imagine that you have the non-fatal chronic disease described previously.	The yearly treatment course includes getting 2 infusions lasting 15–30 minutes at the hospital.	
	You get treatment for it every year.	There will be no risk of serious long-term side effects (softening of/fractured bones).	
	Each treatment consists of getting 2 infusions lasting 15-30 minutes at the hospital.		
	There will be no risk of serious long-term side effects (softening of/fractured bones).		
	This treatment keeps the disease under control.		
	Imagine what it would be like for you to live with this disease and get the described treatment for the rest of your life.		
7	We would now like you to imagine that you have the non-fatal chronic disease described previously.	The yearly treatment course includes getting 2 infusions lasting 15–30 minutes at the hospital.	
	You get treatment for it every year.	1 out of 1000 patients experience serious long-term side effects (softening of/fractured bones).	
	Each treatment consists of getting 2 infusions lasting 15-30 minutes at the hospital.		
	1 out of 1000 patients experience serious long-term side effects (softening of/fractured bones).		
	This treatment keeps the disease under control.		
	Imagine what it would be like for you to live with this disease and get the described treatment for the rest of your life.		

Incremental infusions	Disutility, mean (95% confidence interval)	Marginal disutility, mean (95% confidence interval)
0	0	NA
1	0.016 (0.0095 to 0.024)	0.0063 (0.0052 to 0.0071)
2	0.021 (0.0138 to 0.029)	0.0042 (0.0038 to 0.0044)
3	0.025 (0.0172 to 0.033)	0.0032 (0.0031 to 0.0033)
4	0.028 (0.0201 to 0.036)	0.0027 (0.0027 to 0.0027)
5	0.030 (0.0227 to 0.038)	0.0024 (0.0023 to 0.0025)
6	0.033 (0.0251 to 0.041)	0.0021 (0.0020 to 0.0023)
7	0.035 (0.0273 to 0.043)	0.0019 (0.0018 to 0.0021)
8	0.036 (0.0293 to 0.044)	0.0018 (0.0016 to 0.0020)
9	0.038 (0.0313 to 0.046)	0.0017 (0.0015 to 0.0019)
10	0.040 (0.0331 to 0.047)	0.0016 (0.0014 to 0.0018)
11	0.041 (0.0349 to 0.049)	0.0015 (0.0013 to 0.0017)
12	0.043 (0.0366 to 0.050)	0.0014 (0.0012 to 0.0017)
13	0.044 (0.0382 to 0.051)	0.0013 (0.0012 to 0.0016)
14	0.045 (0.0398 to 0.052)	0.0013 (0.0011 to 0.0015)
15	0.047 (0.0413 to 0.053)	0.0012 (0.0011 to 0.0015)

Table S3Calculated disutilities and marginal disutilities from the power function for upto 15 infusions